CA3144790A1 - Antibody-drug conjugate, intermediate thereof, preparation method therefor and application thereof - Google Patents

Antibody-drug conjugate, intermediate thereof, preparation method therefor and application thereof Download PDF

Info

Publication number
CA3144790A1
CA3144790A1 CA3144790A CA3144790A CA3144790A1 CA 3144790 A1 CA3144790 A1 CA 3144790A1 CA 3144790 A CA3144790 A CA 3144790A CA 3144790 A CA3144790 A CA 3144790A CA 3144790 A1 CA3144790 A1 CA 3144790A1
Authority
CA
Canada
Prior art keywords
antibody
seq
amino acid
acid sequence
sequence listing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3144790A
Other languages
English (en)
French (fr)
Inventor
Bin BAO
Qingsong GUO
Bei GAO
Yifan Zhang
Xuefei QIU
Tong Yang
Yijun Shen
Wenbo Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Fudan Zhangjiang Bio pharmaceutical Co Ltd
Original Assignee
Shanghai Fudan Zhangjiang Bio pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Fudan Zhangjiang Bio pharmaceutical Co Ltd filed Critical Shanghai Fudan Zhangjiang Bio pharmaceutical Co Ltd
Publication of CA3144790A1 publication Critical patent/CA3144790A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3144790A 2019-06-28 2020-06-05 Antibody-drug conjugate, intermediate thereof, preparation method therefor and application thereof Pending CA3144790A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910577909.6 2019-06-28
CN201910577909 2019-06-28
PCT/CN2020/094767 WO2020259258A1 (zh) 2019-06-28 2020-06-05 一种抗体偶联药物、其中间体、制备方法及应用

Publications (1)

Publication Number Publication Date
CA3144790A1 true CA3144790A1 (en) 2020-12-30

Family

ID=74059658

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3144790A Pending CA3144790A1 (en) 2019-06-28 2020-06-05 Antibody-drug conjugate, intermediate thereof, preparation method therefor and application thereof

Country Status (9)

Country Link
US (1) US20220233708A1 (https=)
EP (1) EP3991754A4 (https=)
JP (1) JP7407845B2 (https=)
KR (1) KR20220025861A (https=)
CN (1) CN113766933B (https=)
AU (1) AU2020301289B2 (https=)
BR (1) BR112021026580A2 (https=)
CA (1) CA3144790A1 (https=)
WO (1) WO2020259258A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023042097A1 (en) * 2021-09-15 2023-03-23 Daiichi Sankyo Company, Limited Antibody-drug conjugate for use in methods of treating chemotherapy-resistant cancer

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230054458A1 (en) * 2019-12-12 2023-02-23 Jiangsu Hengrui Medicine Co., Ltd. Anti-claudin antibody-drug conjugate and pharmaceutical use thereof
AU2021289927A1 (en) * 2020-06-08 2023-01-19 Systimmune, Inc. Camptothecin drug having high-stability hydrophilic connecting unit and conjugate thereof
WO2021252708A1 (en) * 2020-06-11 2021-12-16 President And Fellows Of Harvard College Stabilized trioxacarcin antibody drug conjugates and uses thereof
JP7753372B2 (ja) * 2020-10-12 2025-10-14 シーチュアン バイリ ファーム シーオー． エルティーディー 重水素化カンプトテシン系誘導体及びその抗体薬物複合体
EP4257153B1 (en) * 2020-12-04 2025-11-12 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Antibody-drug conjugate, and intermediate thereof, preparation method therefor, and application thereof
CN116583526B (zh) * 2020-12-11 2025-09-26 微境生物医药科技(上海)有限公司 新型喜树碱衍生物、含其的组合物和其用途
JP7564958B2 (ja) * 2020-12-18 2024-10-09 シャンハイ フダン－チャンジャン バイオ－ファーマシューティカル カンパニー リミテッド Ｂ７－ｈ３を標的とする抗体薬物複合体、その製造方法と使用
EP4265275A4 (en) * 2020-12-18 2024-03-20 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. ANTIBODY-DRUG CONJUGATE TARGETING TROP2, PREPARATION METHOD AND USE THEREOF
CN114805377A (zh) * 2021-01-29 2022-07-29 明慧医药（杭州）有限公司 适用于抗体-药物偶联物的毒素分子
WO2022171115A1 (zh) * 2021-02-09 2022-08-18 微境生物医药科技(上海)有限公司 用于adc制备的喜树碱衍生物
CN116897149A (zh) * 2021-03-30 2023-10-17 上海复旦张江生物医药股份有限公司 一种连接基药物偶联物的制备方法及其中间体
CN116867789B (zh) * 2021-03-31 2025-06-24 上海复旦张江生物医药股份有限公司 一种伊喜替康衍生物的制备方法及其中间体
CN115385926B (zh) * 2021-05-24 2025-06-03 上海复旦张江生物医药股份有限公司 一种连接基药物偶联物的制备方法及其中间体
IL309457A (en) * 2021-06-17 2024-02-01 Minghui Pharmaceutical Hangzhou Ltd Compound against tumors and its use
CN117715913A (zh) * 2021-07-19 2024-03-15 芝诺管理公司 免疫缀合物和方法
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
TW202320858A (zh) 2021-07-19 2023-06-01 美商薩諾管理公司 免疫接合物及方法
WO2023006084A1 (zh) 2021-07-30 2023-02-02 上海复旦张江生物医药股份有限公司 一种抗dll3抗体及其制备方法、其药物偶联物和应用
KR20240082348A (ko) * 2021-09-27 2024-06-10 에보포인트 바이오사이언시스 컴퍼니 리미티드 항체, 이의 항체-약물 접합체 및 이의 용도
CN118401258A (zh) * 2021-12-09 2024-07-26 昆山新蕴达生物科技有限公司 一种亲和力改善的抗体-药物偶联物、其制备方法及应用
CN119317447A (zh) 2022-04-12 2025-01-14 米纳瓦生物技术公司 抗可变muc1*抗体及其用途
WO2024008102A1 (en) * 2022-07-05 2024-01-11 Wuxi Xdc (Shanghai) Co., Ltd. Linker for conjugation
EP4558506A1 (en) * 2022-07-22 2025-05-28 NJ Bio, Inc. Hexacyclic topoisomerase inhibitors having cytotoxic activity on cancer cells
EP4562051A1 (en) * 2022-07-26 2025-06-04 Immunome, Inc. Immunoconjugates and methods
JP2025524970A (ja) * 2022-07-27 2025-08-01 明慧医藥（杭州）有限公司 抗体－薬物コンジュゲートおよびその使用
CN117510515A (zh) * 2022-07-28 2024-02-06 明慧医药（杭州）有限公司 适用于抗体-药物偶联物的毒素分子
WO2024091437A1 (en) * 2022-10-25 2024-05-02 Merck Sharp & Dohme Llc Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
EP4623936A1 (en) * 2022-11-22 2025-10-01 Keymed Biosciences (Chengdu) Co., Ltd. Fused ring compound, conjugate thereof and use thereof
KR20250111373A (ko) * 2022-11-25 2025-07-22 밍훼이 파마슈티컬 (항저우) 리미티드 항종양 화합물 및 이의 응용
WO2024114667A1 (zh) * 2022-11-30 2024-06-06 正大天晴药业集团股份有限公司 抗cldn18.2抗体药物偶联物及其药物组合物和用途
CN116178386B (zh) 2022-12-30 2025-09-09 上海复旦张江生物医药股份有限公司 一种连接基药物偶联物的制备方法及其中间体
CN116217655B (zh) * 2022-12-30 2025-09-23 上海复旦张江生物医药股份有限公司 一种连接基药物偶联物的中间体的制备方法
CN116217654B (zh) * 2022-12-30 2025-09-26 上海复旦张江生物医药股份有限公司 一种连接基药物偶联物的制备方法及其中间体
JPWO2024214685A1 (https=) 2023-04-10 2024-10-17
WO2025021152A1 (zh) * 2023-07-26 2025-01-30 上海医药集团股份有限公司 喜树碱类小分子及其抗体药物偶联物、制备方法和应用
WO2025049270A1 (en) * 2023-08-25 2025-03-06 Macrogenics, Inc. B7-h3 antibody-drug conjugates
WO2025106278A1 (en) 2023-11-17 2025-05-22 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates
WO2025238587A1 (en) 2024-05-16 2025-11-20 Daiichi Sankyo Company, Limited Combination of anti-b7-h3 antibody-drug conjugate and androgen receptor signaling inhibitor
CN120617538B (zh) * 2025-07-21 2026-04-03 南京滴力生物科技有限公司 一种用于治疗肿瘤的抗体药物偶联物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
EP2240495B1 (en) * 2008-02-01 2015-07-15 Genentech, Inc. Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
NZ610239A (en) * 2008-04-30 2014-11-28 Immunogen Inc Cross-linkers and their uses
ES2647317T3 (es) * 2008-11-03 2017-12-20 Syntarga B.V. Análogos de CC-1065 y sus conjugados
WO2013173337A2 (en) * 2012-05-15 2013-11-21 Seattle Genetics, Inc. Self-stabilizing linker conjugates
ES2773710T3 (es) * 2012-10-11 2020-07-14 Daiichi Sankyo Co Ltd Enlazadores para conjugados de anticuerpo - fármaco
IL310627B2 (en) * 2014-01-31 2026-04-01 Daiichi Sankyo Co Ltd Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof
JP2017114763A (ja) 2014-03-26 2017-06-29 第一三共株式会社 抗ｃｄ９８抗体−薬物コンジュゲート
EP3209334A2 (en) * 2014-10-20 2017-08-30 Igenica Biotherapeutics, Inc. Novel antibody-drug conjugates and related compounds, compositions, and methods of use
EP4321523A3 (en) * 2017-08-10 2024-04-24 Sumitomo Pharma Co., Ltd. Hemiasterlin derivatives and antibody-drug conjugates including same
WO2019034176A1 (zh) * 2017-08-18 2019-02-21 四川百利药业有限责任公司 一种喜树碱-抗体偶联物
WO2019034177A1 (zh) * 2017-08-18 2019-02-21 四川百利药业有限责任公司 具有两种不同药物的抗体药物偶联物
CN109200291B (zh) * 2018-10-24 2021-06-08 中国医学科学院医药生物技术研究所 一种靶向于egfr的抗体偶联药物及其制备方法和其用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023042097A1 (en) * 2021-09-15 2023-03-23 Daiichi Sankyo Company, Limited Antibody-drug conjugate for use in methods of treating chemotherapy-resistant cancer

Also Published As

Publication number Publication date
EP3991754A1 (en) 2022-05-04
CN113766933B (zh) 2024-09-06
JP7407845B2 (ja) 2024-01-04
KR20220025861A (ko) 2022-03-03
JP2022542222A (ja) 2022-09-30
US20220233708A1 (en) 2022-07-28
EP3991754A4 (en) 2023-05-17
AU2020301289B2 (en) 2024-11-07
BR112021026580A2 (pt) 2022-05-03
CN113766933A (zh) 2021-12-07
WO2020259258A1 (zh) 2020-12-30
AU2020301289A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
CA3144790A1 (en) Antibody-drug conjugate, intermediate thereof, preparation method therefor and application thereof
CA3206117A1 (en) Bioactive substance conjugate, preparation method therefor and use thereof
CA3238578A1 (en) Antibody-drug conjugate and use thereof
CA3183184A1 (en) Camptothecin analogs conjugated to a glutamine residue in a protein, and their use
JP2022517040A (ja) Ｃｄ３８に特異的な二環式ペプチドリガンド
AU2021230226B2 (en) Antibody-drug conjugate including novel cyclic dinucleotide derivative
KR102941238B1 (ko) 캄토테신 약물 및 그의 항체 접합체
CN117731798A (zh) 抗体偶联药物、其中间体、制备方法及应用
CA3202303C (en) Trop2 targeting antibody-drug conjugate, and preparation method and use therefor
US20240398970A1 (en) B7-h3 targeting antibody-drug conjugate, and preparation method therefor and use thereof
US20010056178A1 (en) Deoxo-proline-containing tamandarin and didemnin analogs, dehydro-proline-containing tamandarin and didemnin analogs, and methods of making and using them
CN117298291A (zh) Fc结合肽偶联物、靶向TROP2的定点偶联ADC及其制备方法和应用
EP4257153B1 (en) Antibody-drug conjugate, and intermediate thereof, preparation method therefor, and application thereof
US20240368225A1 (en) Selective small molecule agonists and partial agonists of trk receptors
JP2022515721A (ja) ＦＡＰαに特異的な二環式ペプチドリガンド
RU2800137C1 (ru) Конъюгат антитело-лекарственное средство, промежуточное соединение для его получения, способ его получения и его применение
CA3200812C (en) Antibody-drug conjugate, and intermediate thereof, preparation method thereof, and application thereof
CN114642740A (zh) 一种靶向trop2的抗体药物偶联物、其制备方法及应用
CN120303002A (zh) 包含抗肿瘤剂的聚合化合物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220128

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250410

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250415

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250415

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250808

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250813

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250822

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250909

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250917

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250917